Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer.

ABSTRACT: Non-small cell lung cancer (NSCLC) is the most common cause of cancer mortality. Although a significant proportion of patients can be cured with surgery, with or without adjuvant or neoadjuvant chemotherapy and radiation, a significant proportion of patients will fail, particularly distantly. Over fifty percent of patients present with stage IV disease. There are multiple forms of immunotherapy available including T-cell transfer, cytokine therapy, and oncolytic viruses. Checkpoint inhibitors have shown tremendous activity in NSCLC and are currently under intense study given promising data on response. Immunotherapy and radiation therapy (RT) both show significant immune editing activity in NSCLC that may allow the innate and adaptive immune system to help control systemic disease by both

SUBMITTER: Taunk NK 

PROVIDER: S-EPMC5420541 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature